Repair and regeneration of ocular tissue using postpartum-derived cells

• US 8,790,637 B2
• Filed: 03/25/2008
• Issued: 07/29/2014
• Est. Priority Date: 06/27/2003
• Status: Active Grant

• Current Assignee: Depuy Synthes Products Incorporated (Johnson & Johnson)
• Original Assignee: DePuy Synthes Products LLC (Johnson & Johnson)
• Inventors: Mistry, Sanjay, Messina, Darin
• Primary Examiner(s): DUNSTON, JENNIFER ANN
• Application Number:
  US12/054,718
• Publication Number:
  US 20100272803A1
• Time in Patent Office: 2,317 Days
• Field of Search: None
• US Class Current: 424/93.7
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: C12N 2500/32 Amino acids
• CPC Class Codes: C12N 2500/34 Sugars
• CPC Class Codes: C12N 2500/44 Thiols, e.g. mercaptoethanol
• CPC Class Codes: C12N 2500/90 Serum-free medium, which may still contain naturally-sourced components
• CPC Class Codes: C12N 2500/95 Protein-free medium and culture conditions
• CPC Class Codes: C12N 2501/12 Hepatocyte growth factor [HGF]
• CPC Class Codes: C12N 2501/21 Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
• CPC Class Codes: C12N 2501/23 Interleukins [IL]
• CPC Class Codes: C12N 2502/02 embryonic cells
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2506/025 from extra-embryonic cells, e.g. trophoblast, placenta
• CPC Class Codes: C12N 2506/03 from non-embryonic pluripotent stem cells
• CPC Class Codes: C12N 2506/08 from cells of the nervous system
• CPC Class Codes: C12N 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 2533/50 Proteins
• CPC Class Codes: C12N 5/0605 : Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0607 : Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12N 5/0618 : Cells of the nervous system

Abstract

Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of ocular tissue using the postpartum-derived cells are also disclosed.

Claims

1. A method for treating damage to the optic nerve in a patient having glaucoma, the method comprising administering to the damaged optic nerve isolated umbilicus-cells isolated from human umbilical cord tissue substantially free of blood, in an amount effective to treat the damage, wherein the cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, maintain a normal karyotype upon passaging, and have the following characteristics:

a) potential for at least 40 population doublings in culture;

b) production of CD10, CD13, CD44, CD73, and CD90;

c) lack of production of CD31, CD34, CD45, CD117 and CD141, and

d) increased expression of genes encoding interleukin 8 and reticulon 1 relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.

2. The method of claim 1, wherein the umbilicus cells are positive for HLA-A,B,C, and negative for HLA-DR,DP,DQ.

3. The method of claim 1, wherein the umbilicus cells are expanded in culture prior to administering to the patient'"'"'s eye.

4. The method of claim 1, wherein the umbilicus cells are administered with at least one other agent.

5. The method of claim 4, wherein the at least one other agent is administered simultaneously with, or before, or after, the umbilicus cells.

6. The method of claim 1, wherein the umbilicus cells are administered through a cannula or from a device inserted in the patient'"'"'s eye.

7. The method of claim 1, wherein the umbilicus cells are administered by insertion of a matrix or scaffold containing the cells.

8. A method for reducing the loss of photoreceptor cells in a patient with a retinal degeneration, the method comprising administering to the interior of the patient'"'"'s eye isolated umbilicus cells isolated from human umbilical cord tissue substantially free of blood, in an amount effective to reduce the loss of photoreceptor cells, wherein the umbilicus cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, maintain a normal karyotype upon passaging, and have the following characteristics:

a) potential for at least 40 population doublings in culture;

b) production of CD10, CD13, CD44, CD73, and CD90;

c) lack of production of CD31, CD34, CD45, CD117, and CD141, and

d) increased expression of genes encoding interleukin 8 and reticulon 1 relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.

9. The method of claim 8, wherein the umbilicus cells are positive for HLA-A,B,C, and negative for HLA-DR,DP,DQ.

10. The method of claim 8, wherein the umbilicus cells are expanded in culture prior to administering to the patient'"'"'s eye.

11. The method of claim 8, wherein the retinal degeneration is age-related macular degeneration.

12. The method of claim 8, wherein the loss of photoreceptor cells is reduced by inhibiting the apoptosis of the photoreceptor cells.

13. The method of claim 8, wherein the loss of photoreceptor cells is reduced by stimulating the phagocytosis of shed photoreceptor fragments.

14. The method of claim 13, wherein trophic factors secreted by the umbilicus cells stimulate retinal pigment epithelial (RPE) cells to phagocytose the shed photoreceptor fragments.

15. The method of claim 13, wherein the umbilicus cells stimulate the phagocytosis of shed photoreceptor fragments by retinal pigment epithelium (RPE) cells.

16. The method of claim 8, wherein the umbilicus cells are administered with at least one other agent.

17. The method of claim 16, wherein the at least one other agent is administered simultaneously with, or before, or after, the umbilicus cells.

18. The method of claim 8, wherein the umbilicus cells are administered through a cannula or from a device inserted in the patient'"'"'s eye.

19. The method of claim 8, wherein the umbilicus cells are administered by insertion of a matrix or scaffold containing the umbilicus cells.

20. The method of claim 11, wherein the age-related macular degeneration is dry age-related macular degeneration.